$2.98−$0.1100 (−3.56%) on the dayAs of the close; data may be delayed.
COYA price, last 12 months
$6.51$2.81
Daily closes over the last 260 trading sessions: −48.3%. Highest close $6.51 on , lowest $2.81 on . Market data may be delayed.
Key stats
Previous close
$3.09
Open
$3.11
Day range
$2.98 – $3.24
52-week range
$2.72 – $6.62
Volume
71.2K
Avg volume (20 days)
181.7K
Market cap
$73.4M
Performance
1W−5.8%
1M−28.7%
3M−40.5%
6M−38.7%
YTD−49.1%
1Y−49.1%
vs S&P 500, 1Y−53.2 pts
Technicals and fundamentals
About Coya Therapeutics, Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
Chart COYA with indicators, scan for setups and get alerts
This page is open to everyone. A free ScanPro account adds the interactive parts, along with watchlists, paper trading with simulated money and the Academy's quizzes.
A full COYA chart with indicator overlays, pattern markers and daily, weekly or intraday bars.
Scans of a whole index or list with 72 named conditions, 26 chart setups or a formula of your own.
Alerts and notifications when one fires on a stock you watch, on delayed market data.
Daily range (ATR)10.0%average true range, % of price
52w low $2.7252w high $6.62
Where price sits today against its own history. A description, not a forecast.
Valuation
P/E (trailing)—
P/E (forward)−1.5
PEG—
Price / sales14.71
Price / book2.06
EV / EBITDA—
Company figures as of Nov 20, 2026.
Analysts
ConsensusStrong buy1.0 on 1 (strong buy) to 5 (strong sell)
Analysts7
Average target$15.21+415.7% from today
Price targets are opinions and tend to lean optimistic.
Earnings
Next results, expectedaround Mar 15, 2027 (in 114 days)A year after its Mar 16, 2026 results release; the last came Nov 10, 2026. An estimate from its SEC filings, not a date the company announced.
Seasonality
-11.1
J
+17.9
F
-5.4
M
+5.4
A
-7.1
M
-0.0
J
-3.5
J
-1.1
A
+3.1
S
+4.5
O
+2.0
N
+5.3
D
Average return in each calendar month, Jan 31, 2023 to Oct 31, 2026. 4 years is 4 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.
Year by year
Year
J
F
M
A
M
J
J
A
S
O
N
D
Year
2026
−20
+7
−21
+7
+14
+21
−28
+9
+10
−28
−38%
2025
+6
+16
−9
+2
−19
+8
+3
+10
−13
+11
+3
−11
+1%
2024
−20
+52
+10
−9
−16
−20
+13
−12
+7
+12
−10
−12
−23%
2023
−10
−4
−3
+21
−7
−9
−2
−11
+9
+23
+13
+39
+56%
Each year's monthly returns in %, the observations behind the averages. The last column compounds the year's months; a year the history only partly covers is faded.
Financials
As reported in the company's SEC filings. Latest: Q3 FY2026, ended Sep 30, 2026.
Free shows the latest quarter, the latest year and the last 12 months. Plus shows every period and the growth figures.See Plus
Figures are as each 10-Q and 10-K reported them, in the company's own fiscal calendar, not restated later. A company that changes how it reports a line can make one period look out of step with the rest. Growth compares the same period a year earlier and is left blank when the year before was a loss. Banks and insurers report no gross profit, so rows they don't file are left out. Every filing on SEC EDGAR
News
No recent news stored for this stock.
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.
Figures describe the past, not what the price will do next. Educational tools, not investment advice.